CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Discover why CVS' turnaround may be underway with improved medical cost trends, segment growth, and raised FY2025 guidance.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to ... how much the CVS formulary change will ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

It is alleged that CVS falsely overbilled state Medicaid programs for prescription drugs dispensed at its retail pharmacies.